Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease

NCT06189963 is registered in ClinicalTrials.gov with NKGen Biotech, Inc. as lead sponsor.

NCT NCT06189963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06189963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease
Lead sponsor
NKGen Biotech, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 21, 2023
Completion date
June 30, 2028
Enrollment
36 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

moderate alzheimer disease